/
/
Attacking AML Cells with a New Immunotherapy Infusion with Kendra Sweet, MD, Moffitt Cancer Cen...

Event Description

IF YOU WOULD PREFER TO JOIN THE SHOW BY PHONE, PLEASE CALL (515) 602-9728

*you need to join by phone if you want to ask Dr. Sweet your questions.

Immunotherapy continues to be an expanding and evolving area of research for AML, with many drugs in development. One drug currently being studied is IMGN632, an antibody drug conjugate, that targets CD123-positive AML cells. IMGN632 has shown promising results in relapsed/refractory patients in previous AML trials. 

Join us live on Thursday, June 9th at 1 PM EST to learn from Dr. Kendra Sweet, an AML expert from Moffitt Cancer Center in Tampa, Florida, about IMGN632, an exciting new immunotherapy investigational agent.

During the show, Dr. Sweet will discuss what IMGN632 is, how it is helping AML patients and the current trial she is participating in that is testing IMGN632 alone, as monotherapy, or when used in combination with other frontline AML drugs. Learn all about immunotherapy and the role it can play when added to existing AML treatment modalities. There will be time at the end of the show to directly ask Dr. Sweet your questions! 

Thank you to our episode sponsor, Bristol Myers Squibb.

Schedule & Agenda

01:00PM - 02:00PM
01:00PM
Kerith Amen
Welcome
Welcome, Announcements and Introduction
01:05PM
Dr. Kendra Sweet
Interview
Dr. Sweet will discuss what IMGN632 is, how it is helping AML patients and the current trial she is participating in that is testing IMGN632.
01:50PM
Audience
Questions & Answers
Audience is able to call in to the radio show, (515) 602-9728, to ask Dr. Sweet questions about what was discussed during our interview today.

Speakers & Moderators

The author Kerith Amen
Kerith Amen
New Orleans, Louisiana

Kerith joined HealthTree Foundation as a Community Co-Director for AML in 2022. She is a mother to a spirited eight-year-old daughter, Adair, and their beloved rescue, Violet. She lost her best friend and husband, Rob, to AML in March 2018. Kerith wishes she had a resource such as HealthTree for AML during Rob’s illness. She is a strong supporter of HealthTree's mission. She hopes that by sharing her experience, she may help other patients and caregivers navigate an AML diagnosis.

The author Kendra Sweet, MD
Kendra Sweet, MD
Tampa, FL

Dr. Kendra Sweet is an Associate Member in the Department of Malignant Hematology at Moffitt Cancer Center. Dr. Sweet's clinical interests include myeloid malignancies with a particular focus on acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Have Any Questions?

Thank you for your interest in the event. If you have any question, we would love to help! Just fill out the form below and we will get back to you as quickly as possible.

support

Get In Touch With Us

phone

(800) 930-5159

email

Support@healthtree.org

Get the latest thought leadership on AML delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for AML Newsletter" for AML news, life with AML stories, AML clinical trials, AML 101 articles and events with AML experts.

Thanks to our HealthTree Community for AML Sponsors:

Bristol Myers Squibb
Jazz Pharmaceuticals
AbbVie
Genentech
Amgen

Follow Us

facebook instagram twitter youtube

 

Terms of Use and Privacy Policy     Newsroom     About    Donations    Find an AML Specialist     Newsletter     Learn     Connect

 

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / HealthTree for AML is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

https://www.guidestar.org/profile/45-5354811